Global Search

Hide Filters

Showing 1136 results

Press release / Oct 28, 2017

Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a

PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a Currently there are no specifically approved disease…
Press release / Oct 25, 2017

Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS

Full data from the pivotal Phase III PARADIGMS study of Gilenya® (fingolimod) in pediatric MS will be presented for the first time With 54 accepted abstracts, Novartis presence spans from…
Press release / Sep 15, 2016

Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine

Detailed results from Phase II study in chronic migraine prevention showed patients on AMG 334 (erenumab) were significantly more likely to experience a 50% or more reduction in monthly migraine…
Press release / Dec 05, 2016

Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec®

ENESTop post-hoc analysis provides further insights into Treatment-free Remission (TFR) among Ph+ CML switch patients[1] The Tasigna TFR trials, including ENESTop, demonstrate our continued…
Press release / Apr 24, 2017

Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS

Over 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression; around 58% showed brain shrinkage levels broadly within the…
Press release / Jan 31, 2017

Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC

Votubia is the first adjunctive treatment approved in the EU specifically for partial-onset seizures in children and adults with tuberous sclerosis complex (TSC) Approval addresses unmet…
Press release / Dec 12, 2016

Novartis lance SMS for Life 2.0 au Nigeria pour aider à améliorer l'accès aux médicaments essentiels

SMS for Life 2.0 est lancé pour la première fois dans l'Etat de Kaduna, troisième région la plus peuplée du Nigeria, en collaboration avec le ministère de la Santé de l'Etat de Kaduna. Ce…
Press release / Nov 12, 2017

New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure

Entresto reversed trend of worsening New York Heart Association (NYHA) class - a key measure of the severity of a patient's heart failure symptoms - improving common…
Press release / Oct 31, 2017

Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy

Submission based on updated analyses from global, multi-center Phase II JULIET study, which met primary endpoint, including 6-month data to be presented at ASH 2017 Kymriah has demonstrated…
Press release / Jun 28, 2018

Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine

Results from a one-year study of efficacy and safety of Aimovig in chronic migraine and data from a three-year analysis assessing safety and tolerability of Aimovig in episodic migraine will be…

‹ Previous page
1
…
85
86
87
88
89
90
91
…
114
› Next page